pharmaphorum9d
Is GSK’s Blenrep heading for a renaissance?
A year after GSK pulled its BCMA-targeting antibody-drug conjugate (ADC) Blenrep from the US market as a later-line therapy for multiple myeloma, there are signs that the drug may still have a ...
Hosted on MSN8mon
GSK’s Blenrep combo therapy meets key goal in multiple myeloma trial
The trial evaluated Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex. A pre-specified interim ...
pharmaphorum2y
GSK's Blenrep hopes take a knock as drug fails trial
While Blenrep has been granted accelerated approval by the FDA for multiple myeloma patients who have received at least four prior therapies – including an anti-CD38 monoclonal antibody, a ...
Hosted on MSN3mon
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
However, in November 2022, Blenrep was withdrawn from the U.S. market after the failure of GSK’s phase III confirmatory study, DREAMM-3, which evaluated Blenrep in patients with relapsed or ...
London South East1mon
GSK says Blenrep combinations accepted for review in Japan
(Alliance News) - GSK PLC on Tuesday said its Blenrep cancer treatment will undergo review in Japan after successful authorisations recently in the UK and Europe. The London-based pharmaceutical ...